利伐沙班在非瓣膜病性房颤患者经导管射频消融术后抗凝中的代谢获益（英文）

发布时间：2018-03-27 15:49

本文选题：心房颤动　切入点：导管射频消融　出处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2017年11期

【摘要】：目的:评估非瓣膜病性房颤患者应用利伐沙班抗凝治疗相较华法林的代谢获益,及利伐沙班应用的安全性和有效性。创新点:首次研究利伐沙班对房颤射频消融术后患者代谢水平影响,评估利伐沙班相较华法林抗凝治疗的代谢获益。方法:前瞻性入选2014年4月至7月共60例行经皮房颤导管射频消融术患者,随机分为利伐沙班治疗组和华法林治疗组。在术后15、30、60和90天检测代谢指标(包括血清总蛋白、白蛋白、球蛋白和高密度脂蛋白(HDL)等)变化,并随访出血、卒中和系统性栓塞事件等发生情况。结论:服用利伐沙班抗凝治疗患者在随访期间血清总蛋白、白蛋白、球蛋白和HDL水平较术前均显著升高,而华法林治疗组患者各项代谢指标呈先下降、后上升趋势。两组均没有发生死亡和栓塞事件,出血并发症发生率亦无明显差异。研究结果表明,非瓣膜病性房颤患者经导管射频消融术后接受利伐沙班抗凝具有代谢方面获益,与华法林相比两者在安全性和有效性方面无明显差异,研究结果可为临床选择合适抗凝方案提供参考。
[Abstract]:Objective: to evaluate the metabolic benefits of warfarin in patients with non-valvular atrial fibrillation treated with rivastaben anticoagulant therapy. Innovation: the effect of rivastabine on the metabolic level of patients with atrial fibrillation after radiofrequency ablation was studied for the first time. Methods: a total of 60 patients undergoing percutaneous catheter radiofrequency ablation of atrial fibrillation from April to July 2014 were prospectively selected to evaluate the metabolic benefits of rivastaban compared with warfarin anticoagulant therapy. The patients were divided into two groups randomly. The metabolic indexes (including serum total protein, albumin, globulin and high density lipoprotein (HDLL)) were measured on the 15th day, 30th day and 90th day after operation, and the patients were followed up with bleeding. Conclusion: the levels of serum total protein, albumin, globulin and HDL in patients treated with rivastaban anticoagulant therapy were significantly higher than those before operation. However, the metabolic indexes of warfarin group decreased first, then increased. There was no death or embolism, and there was no significant difference in the incidence of bleeding complications between the two groups. Patients with non-valvular atrial fibrillation received rivastaben after radiofrequency catheter ablation had metabolic benefits. There was no significant difference in safety and efficacy between the two groups compared with warfarin. The results can provide a reference for clinical selection of appropriate anticoagulant regimen.
【作者单位】： Department
【分类号】：R541.75

【相似文献】